CX717
CX717 je ampakinsko jedinjenje koje je razvila kompanija Korteks farmaceutikals.[1] CX717 utiče na neurotransmiter glutamat. Ispitivanja su pokazala da ovaj lek poboljšava kognitivne funkcije i memoriju.[2]
| Klinički podaci | |
|---|---|
| Identifikatori | |
| CAS broj | 867276-98-0 |
| ATC kod | nije dodeljen |
| Hemijski podaci | |
| Formula | ? |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | oralno, IV |
Reference uredi
- ↑ „Benzofurazan compounds for enhancing glutamatergic synaptic responses”. Arhivirano iz originala na datum 2012-09-05. Pristupljeno 04. 04. 2008.
- ↑ Hampson RE, España RA, Rogers GA, Porrino LJ, Deadwyler SA (January 2009). „Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717”. Psychopharmacology 202 (1-3): 355–69. DOI:10.1007/s00213-008-1360-z. PMID 18985324.
Literatura uredi
- Bast T, da Silva BM, Morris RG (2005). „Distinct contributions of hippocampal NMDA and AMPA receptors to encoding and retrieval of one-trial place memory”. J. Neurosci. 25 (25): 5845–56. DOI:10.1523/JNEUROSCI.0698-05.2005. PMID 15976073.
- Arai AC, Kessler M, Rogers G, Lynch G (2000). „Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466”. Mol. Pharmacol. 58 (4): 802–13. PMID 10999951.
- Porrino LJ, Daunais JB, Rogers GA, Hampson RE, Deadwyler SA (2005). „Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates”. PLoS Biol. 3 (9): e299. DOI:10.1371/journal.pbio.0030299. PMC 1188239. PMID 16104830.
- Cortex Pharmaceuticals press release
